Advaxia Biologics, a member of the IRBM Group, is a CDMO based near Rome, Italy, specializing in the development and production of clinical lots of recombinant adenoviruses for use in vaccine and gene therapy clinical trials. Advaxia provides cGMP manufacturing, analytical development, process development, in-process assay development and qualification, full QC product release, ICH stability, and cell banking. The company has a proven track record in producing clinical lots for infectious diseases, including Ebola and HIV.